Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Comment by 99942Apophison Jun 17, 2022 5:40pm
207 Views
Post# 34765861

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Not long until the AGM

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Not long until the AGM
Good points Eoganacht, my thought is not unlike many here that as hospitals in both countries clear away the backlog of elective surgery we should see less patient strain/anxiety in our PH2 trial thus moving the CR rates higher. As CancerSlayer once said within this trial we have our own comparative groups in the undertreated and the optimized, will Dr. Sherri McFarland  use this in her discussion? My point is again like many here that we should see increasing CR in each upcoming release of Newsletter updates. 
My biggest hope is that Dr. Sherri McFarland attend the AGM one day after Theralase proves this isn't a pipe dream,  if she does attend she will be treated like a celebrity.


Eoganacht wrote
Dr. McFarland will likely be revealing to the rest of the world the same data we TLT-heads have been going over for months, as we try to squeeze a little extra insight from the bare facts revealed in the news releases. The difference is that Dr. McFarland is in a better position to better understand the significance of some of the factual tidbits that may have gone over our heads.


fredgoodwinson wrote: That`s understood - although some of her past published comments have suggested greater operational insight than mine (for example!).




<< Previous
Bullboard Posts
Next >>